Contains Nonbinding Recommendations

Guidance on Miglustat

This guidance represents the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Miglustat

Form/Route: Capsule/Oral

Recommended studies: 2 studies

1. Type of study: Fasting
   Design: single-dose, two-way crossover in-vivo
   Strength: 100 mg
   Subjects: Normal healthy males and females, general population. Females should not be pregnant, and if applicable, should practice abstention or contraception during the study.
   Additional Comments: Pregnancy Category X. Miglustat may cause fetal harm when administered to a pregnant woman. The drug is contraindicated in women who are or may become pregnant.

______________________________________________________________________________

2. Type of study: Fed
   Design: single-dose, two-way crossover in-vivo
   Strength: 100 mg
   Subjects: Normal healthy males and females, general population. Females should not be pregnant, and if applicable, should practice abstention or contraception during the study.
   Additional Comments: Please see comments above.

______________________________________________________________________________

Analytes to measure (in appropriate biological fluid): Miglustat in plasma

Bioequivalence based on (90% CI): Miglustat

Waiver request of in-vivo testing: Not Applicable

Dissolution test method and sampling times:

Please note that a Dissolution Methods Database is available to the public at the OGD website at [http://www.fda.gov/cder/ogd/index.htm](http://www.fda.gov/cder/ogd/index.htm). Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.

Finalized May 2008